相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER-2/neu Overexpression is an Independent Prognostic Factor for Intestinal-type and Early-stage Gastric Cancer Patients
Wei Liu et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
HER2 status in unusual histological variants of gastric adenocarcinomas
Giuseppe Giuffre et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
Agnieszka Halon et al.
SCIENTIFIC WORLD JOURNAL (2012)
Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis
Hai-Zhen Dang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology
Dimitrios Tsapralis et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
Jan Trost Jorgensen et al.
JOURNAL OF CANCER (2012)
HER2 Testing in Gastric Cancer
Luca Albarello et al.
ADVANCES IN ANATOMIC PATHOLOGY (2011)
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Peter C. Thuss-Patience et al.
EUROPEAN JOURNAL OF CANCER (2011)
Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*
Stephen Lee et al.
HISTOPATHOLOGY (2011)
Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)]
Masataka Sawaki et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
The Role of Peri-operative Chemotherapy for Resectable Colorectal Liver Metastasis: What Does the Evidence Support?
Timothy M. Pawlik et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2011)
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni et al.
LANCET ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers
Jens Huober et al.
ONCOLOGY (2011)
Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma
Shi-Yan Yan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
Yassir Sbitti et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2011)
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy
Kaori Fujimoto-Ouchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A study of HER2 gene amplification and protein expression in gastric cancer
Benedict Yan et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report
Jun Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
J. D. Barros-Silva et al.
BRITISH JOURNAL OF CANCER (2009)
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Neil L. Spector et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization
Juliana Bentes Hughes et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer
Junichi Matsubara et al.
CLINICAL CANCER RESEARCH (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival
Reiki Nishimura et al.
BREAST CANCER (2008)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction
Min A. Kim et al.
HUMAN PATHOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
HER-2/neu amplification is an independent prognostic factor in gastric cancer
Dong Il Park et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Amplification of HER-2 in gastric carcinoma:: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
M Tanner et al.
ANNALS OF ONCOLOGY (2005)
Biologic and therapeutic role of HER2 in cancer
S Ménard et al.
ONCOGENE (2003)
Status of c-erbB-2 in gastric adenocarcinoma:: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay
T Takehana et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Update on HER-2 as a target for cancer therapy - Intracellular signaling pathways of ErbB2/HER-2 and family members
MA Olayioye
BREAST CANCER RESEARCH (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
